Chang Ah Ram, Wu Hong-Gyun, Park Charn Il, Jun Yoon Kyung, Kim Chul-Woo
Department of Radiation Oncology, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Ku, 110-744 Seoul, Korea.
Head Neck. 2008 Jul;30(7):852-7. doi: 10.1002/hed.20788.
To evaluate the prognostic value of the expressions of epidermal growth factor receptor (EGFR) and cyclin D1 in early glottic cancer treated with radiotherapy only.
One hundred fifty-one patients with T1-2, N0 glottic cancer who had been treated with radiotherapy at Seoul National University Hospital since 1992 through 2004. Immunohistochemical staining for EGFR and cyclin D1 were performed on the formalin-fixed paraffin-embedded tissues of 25 patients who developed local recurrence and on the tissues of 25 matched patients free from disease. Patterns and degrees of expression were compared between these 2 groups.
High EGFR (p = .047) and high cyclin D1 (p = .040) expressions were both found to be significantly associated with a poor prognosis. No association was found between EGFR and cyclin D1 status (p = .158), but EGFR and cyclin D1 status in combination were found to be significantly associated with local control. The patients with both high EGFR and high cyclin D1 expression had the poorest outcome compared with the others (14 months vs 29 months of median time to progression). Patterns of EGFR and cyclin D1 expression changed after recurrence, but these changes were not found to alter the ultimate prognosis.
The molecular biomarkers, EGFR and cyclin D1 have a prognostic significance in early glottic cancer. These markers in combination seem to play an important role in tumor relapse and may be useful for selecting patients with a poor outcome after radiotherapy.
评估表皮生长因子受体(EGFR)和细胞周期蛋白D1的表达在单纯放疗的早期声门癌中的预后价值。
1992年至2004年在首尔国立大学医院接受放疗的151例T1-2、N0声门癌患者。对25例发生局部复发患者的福尔马林固定石蜡包埋组织以及25例配对的无病患者的组织进行EGFR和细胞周期蛋白D1的免疫组织化学染色。比较这两组之间的表达模式和程度。
发现高EGFR(p = 0.047)和高细胞周期蛋白D1(p = 0.040)表达均与预后不良显著相关。未发现EGFR与细胞周期蛋白D1状态之间存在关联(p = 0.158),但发现EGFR和细胞周期蛋白D1状态联合起来与局部控制显著相关。与其他患者相比,EGFR和细胞周期蛋白D1表达均高者预后最差(中位进展时间分别为14个月和29个月)。复发后EGFR和细胞周期蛋白D1的表达模式发生了变化,但这些变化并未改变最终预后。
分子生物标志物EGFR和细胞周期蛋白D1在早期声门癌中具有预后意义。这些标志物联合起来似乎在肿瘤复发中起重要作用,可能有助于选择放疗后预后不良的患者。